Your browser doesn't support javascript.
loading
Current aspects of the quality of head and neck cancer care - survey of the Scandinavian Society for Head and Neck Oncology.
Ilmarinen, Taru; Bratland, Åse; Tøndel, Hanne; Guðjónsson, Arnar; Gebre-Medhin, Maria; Palmgren, Björn; Mäenpää, Hanna; Bjørndal, Kristine; Grau Eriksen, Jesper.
Affiliation
  • Ilmarinen T; Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Bratland Å; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Tøndel H; Department of Oncology, St. Olavs Hospital, Trondheim, Norway.
  • Guðjónsson A; Department of Otorhinolaryngology-Head and Neck Surgery, Landspitali University Hospital, Reykjavik, Iceland.
  • Gebre-Medhin M; Department of Hematology, Oncology, and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Palmgren B; Department of Otorhinolaryngology-Head and Neck Surgery, Karolinska University Hospital, Stockholm, Sweden.
  • Mäenpää H; Department of Oncology, Tampere University Hospital, Tampere, Finland.
  • Bjørndal K; Department of Otorhinolaryngology - Head and Neck Surgery, Odense University Hospital, Odense, Denmark.
  • Grau Eriksen J; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Acta Otolaryngol ; 144(5-6): 404-408, 2024.
Article de En | MEDLINE | ID: mdl-39109489
ABSTRACT

BACKGROUND:

All Nordic countries have national cancer registries collecting data on head and neck cancer (HNC) incidence and survival. However, there is a lack of consensus on how other quality aspects should be monitored.

AIMS:

We conducted a web-based survey to find opportunities for quality control and improvement.

METHODS:

A web-based survey was sent to one otorhinolaryngology - head and neck (ORL-HN) surgeon, and one oncologist at each Nordic university hospital treating HNC. In total, 42 responses from all 21 university hospitals were included.

RESULTS:

In over half of the university hospitals, an oncologist, an ORL-HN surgeon, a pathologist, a radiologist, and a specialized nurse was always present at the multidisciplinary tumor board (MTB) meeting. Of 42 respondents 35 (83%) agreed that treatment delays were systematically recorded for each patient. Eleven of 21 (52%) oncologists agreed that side-effects of (chemo)radiotherapy were systematically recorded. Less than half of the respondents agreed that complications of surgery, and post-treatment quality of life (QOL) were systematically recorded.

CONCLUSIONS:

In the Nordic countries, the importance of HNC treatment timelines is well acknowledged. There is a lack of consensus on the composition of MTB meeting, and how treatment-related morbidity should be monitored outside clinical trials.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la tête et du cou Limites: Humans Pays/Région comme sujet: Europa Langue: En Journal: Acta Otolaryngol Année: 2024 Type de document: Article Pays d'affiliation: Finlande Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la tête et du cou Limites: Humans Pays/Région comme sujet: Europa Langue: En Journal: Acta Otolaryngol Année: 2024 Type de document: Article Pays d'affiliation: Finlande Pays de publication: Royaume-Uni